Search

Your search keyword '"Xu, KaiLin"' showing total 1,236 results
Start Over Author "Xu, KaiLin"
1,236 results on '"Xu, KaiLin"'

13. Topology-aware Convolutional Neural Network for Efficient Skeleton-based Action Recognition

Author

Xu, Kailin, Ye, Fanfan, Zhong, Qiaoyong, and Xie, Di

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

In the context of skeleton-based action recognition, graph convolutional networks (GCNs) have been rapidly developed, whereas convolutional neural networks (CNNs) have received less attention. One reason is that CNNs are considered poor in modeling the irregular skeleton topology. To alleviate this limitation, we propose a pure CNN architecture named Topology-aware CNN (Ta-CNN) in this paper. In particular, we develop a novel cross-channel feature augmentation module, which is a combo of map-attend-group-map operations. By applying the module to the coordinate level and the joint level subsequently, the topology feature is effectively enhanced. Notably, we theoretically prove that graph convolution is a special case of normal convolution when the joint dimension is treated as channels. This confirms that the topology modeling power of GCNs can also be implemented by using a CNN. Moreover, we creatively design a SkeletonMix strategy which mixes two persons in a unique manner and further boosts the performance. Extensive experiments are conducted on four widely used datasets, i.e. N-UCLA, SBU, NTU RGB+D and NTU RGB+D 120 to verify the effectiveness of Ta-CNN. We surpass existing CNN-based methods significantly. Compared with leading GCN-based methods, we achieve comparable performance with much less complexity in terms of the required GFLOPs and parameters., Comment: Accepted by AAAI 2022

Published
2021

15. Notch1 regulates hepatic thrombopoietin production

Author

Sun, Yueyue, Tong, Huan, Chu, Xiang, Li, Yingying, Zhang, Jie, Ding, Yangyang, Zhang, Sixuan, Gui, Xiang, Chen, Chong, Xu, Mengdi, Li, Zhenyu, Gardiner, Elizabeth E., Andrews, Robert K., Zeng, Lingyu, Xu, Kailin, and Qiao, Jianlin

Published
2024
Full Text
View/download PDF

24. Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial

Author

Zhou, Dian, Sun, Qian, Xia, Jieyun, Gu, Weiying, Qian, Jun, Zhuang, Wanchuan, Yan, Zhiling, Cheng, Hai, Chen, Wei, Zhu, Feng, Qi, Kunming, Li, Depeng, Sang, Wei, Zhu, Lili, Ma, Sha, Li, Hujun, Zhang, Huanxin, Qiu, Tingting, Yan, Dongmei, Zhang, Yanlei, Peng, Shuixiu, Chang, Alex H, Xu, Kailin, and Li, Zhenyu

Published
2024
Full Text
View/download PDF

32. T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity

Author

Cui, Yuanbin, Yuan, Tingjie, Wang, Ying, Zheng, Diwei, Qin, Le, Li, Shanglin, Jiang, Zhiwu, Lin, Shouheng, Guo, Wenjing, Wang, Zhi, Liang, Zhaoduan, Li, Yi, Yao, Yao, Liu, Xingguo, Tang, Qiannan, Tu, Hai-Yan, Zhang, Xu-Chao, Tang, Zhaoyang, Wong, Nathalie, Zhang, Zhenfeng, Qin, Dajiang, Thiery, Jean Paul, Xu, Kailin, and Li, Peng

Published
2023
Full Text
View/download PDF

35. The globalizability of temporal discounting

Author

Ruggeri, Kai, Panin, Amma, Vdovic, Milica, Većkalov, Bojana, Abdul-Salaam, Nazeer, Achterberg, Jascha, Akil, Carla, Amatya, Jolly, Amatya, Kanchan, Andersen, Thomas Lind, Aquino, Sibele D., Arunasalam, Arjoon, Ashcroft-Jones, Sarah, Askelund, Adrian Dahl, Ayacaxli, Nélida, Sheshdeh, Aseman Bagheri, Bailey, Alexander, Barea Arroyo, Paula, Mejía, Genaro Basulto, Benvenuti, Martina, Berge, Mari Louise, Bermaganbet, Aliya, Bibilouri, Katherine, Bjørndal, Ludvig Daae, Black, Sabrina, Lyshol, Johanna K. Blomster, Brik, Tymofii, Buabang, Eike Kofi, Burghart, Matthias, Bursalıoğlu, Aslı, Buzayu, Naos Mesfin, Čadek, Martin, de Carvalho, Nathalia Melo, Cazan, Ana-Maria, Çetinçelik, Melis, Chai, Valentino E., Chen, Patricia, Chen, Shiyi, Clay, Georgia, D’Ambrogio, Simone, Damnjanović, Kaja, Duffy, Grace, Dugue, Tatianna, Dwarkanath, Twinkle, Envuladu, Esther Awazzi, Erceg, Nikola, Esteban-Serna, Celia, Farahat, Eman, Farrokhnia, R. A., Fawad, Mareyba, Fedryansyah, Muhammad, Feng, David, Filippi, Silvia, Fonollá, Matías A., Freichel, René, Freira, Lucia, Friedemann, Maja, Gao, Ziwei, Ge, Suwen, Geiger, Sandra J., George, Leya, Grabovski, Iulia, Gracheva, Aleksandra, Gracheva, Anastasia, Hajian, Ali, Hasan, Nida, Hecht, Marlene, Hong, Xinyi, Hubená, Barbora, Ikonomeas, Alexander Gustav Fredriksen, Ilić, Sandra, Izydorczyk, David, Jakob, Lea, Janssens, Margo, Jarke, Hannes, Kácha, Ondřej, Kalinova, Kalina Nikolova, Kapingura, Forget Mingiri, Karakasheva, Ralitsa, Kasdan, David Oliver, Kemel, Emmanuel, Khorrami, Peggah, Krawiec, Jakub M., Lagidze, Nato, Lazarević, Aleksandra, Lazić, Aleksandra, Lee, Hyung Seo, Lep, Žan, Lins, Samuel, Lofthus, Ingvild Sandø, Macchia, Lucía, Mamede, Salomé, Mamo, Metasebiya Ayele, Maratkyzy, Laura, Mareva, Silvana, Marwaha, Shivika, McGill, Lucy, McParland, Sharon, Melnic, Anișoara, Meyer, Sebastian A., Mizak, Szymon, Mohammed, Amina, Mukhyshbayeva, Aizhan, Navajas, Joaquin, Neshevska, Dragana, Niazi, Shehrbano Jamali, Nieves, Ana Elsa Nieto, Nippold, Franziska, Oberschulte, Julia, Otto, Thiago, Pae, Riinu, Panchelieva, Tsvetelina, Park, Sun Young, Pascu, Daria Stefania, Pavlović, Irena, Petrović, Marija B., Popović, Dora, Prinz, Gerhard M., Rachev, Nikolay R., Ranc, Pika, Razum, Josip, Rho, Christina Eun, Riitsalu, Leonore, Rocca, Federica, Rosenbaum, R. Shayna, Rujimora, James, Rusyidi, Binahayati, Rutherford, Charlotte, Said, Rand, Sanguino, Inés, Sarikaya, Ahmet Kerem, Say, Nicolas, Schuck, Jakob, Shiels, Mary, Shir, Yarden, Sievert, Elisabeth D. C., Soboleva, Irina, Solomonia, Tina, Soni, Siddhant, Soysal, Irem, Stablum, Federica, Sundström, Felicia T. A., Tang, Xintong, Tavera, Felice, Taylor, Jacqueline, Tebbe, Anna-Lena, Thommesen, Katrine Krabbe, Tobias-Webb, Juliette, Todsen, Anna Louise, Toscano, Filippo, Tran, Tran, Trinh, Jason, Turati, Alice, Ueda, Kohei, Vacondio, Martina, Vakhitov, Volodymyr, Valencia, Adrianna J., Van Reyn, Chiara, Venema, Tina A. G., Verra, Sanne E., Vintr, Jáchym, Vranka, Marek A., Wagner, Lisa, Wu, Xue, Xing, Ke Ying, Xu, Kailin, Xu, Sonya, Yamada, Yuki, Yosifova, Aleksandra, Zupan, Zorana, and García-Garzon, Eduardo

Published
2022
Full Text
View/download PDF

49. Impact of tocilizumab on anti‐CD19 chimeric antigen receptor T‐cell therapy in B‐cell acute lymphoblastic leukemia.

Author

Wang, Xiangmin, Zhang, Bingpei, Zhang, Qing, Zhou, Hongyuan, Sun, Qian, Zhou, Yi, Li, Tianci, Zhou, Dian, Shen, Ziyuan, Zhang, Jiaoli, Li, Ping, Liang, Aibin, Zhou, Keshu, Han, Lu, Hu, Yongxian, Yang, Yun, Cao, Jiang, Li, Zhenyu, Xu, Kailin, and Sang, Wei

Subjects
CHIMERIC antigen receptors, LYMPHOBLASTIC leukemia, ACUTE leukemia, TOCILIZUMAB, CYTOKINE release syndrome
Abstract

Background: Tocilizumab is commonly used for the management of chimeric antigen receptor (CAR) T‐cell therapy–associated cytokine release syndrome (CRS). However, it remains unknown whether tocilizumab or its dosage affects the efficacy and safety of CAR T‐cell therapy. The objective of this multicenter retrospective study was to explore the impact of tocilizumab on CAR T‐cell therapy. Methods: In total, 93 patients with B‐cell acute lymphoblastic leukemia (B‐ALL) receiving humanized anti‐CD19 CAR T cells were recruited from May 2016 to November 2022. Forty‐five patients received tocilizumab (tocilizumab group), whereas 48 patients did not (nontocilizumab group). Thirteen patients received >1 dose of tocilizumab. The primary end point was the effect of tocilizumab on the efficacy and safety of CAR T cells. Additionally, proliferation, killing, and cytokine assays of CAR T cells were performed in vitro in the presence of tocilizumab. Results: The median age of the patients was 33 years, with 47 males and 46 females. Patients in the tocilizumab group showed similar complete response (CR) rate, overall survival (OS), and event‐free survival (EFS) compared with the nontocilizumab group. Compared with patients who received ≤1 dose of tocilizumab, receiving >1 dose of tocilizumab did not affect their CR rate, OS, or EFS. In the tocilizumab group, all patients experienced CRS and 26.7% experienced immune effector cell–associated neurotoxicity syndrome (ICANS). In the nontocilizumab group, 64.6% of patients experienced CRS and 8.3% experienced ICANS. Up to 75% of ICANS and 87.5% of grade ≥3 ICANS occurred in the tocilizumab group. In vitro, tocilizumab did not impair the proliferation and killing effects of CAR T cells. Conclusions: Tocilizumab does not affect the efficacy of CAR T cells but may increase the likelihood of ICANS. Tocilizumab does not affect the efficacy of anti‐CD19 chimeric antigen receptor (CAR) T cells and the survival outcome of patients with B‐cell acute lymphoblastic leukemia. Tocilizumab may increase the likelihood of immune effector cell–associated neurotoxicity syndrome after CAR T‐cell therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results